Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CCR3 | P51677 | 1/20 | 0.66 |
| ▸ | MC4R | P32245 | 1/20 | 0.59 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.58 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.55 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.55 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | KDM1A | O60341 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8106831 | 0.98 | CCR3 (0.64) | CCR3MC4RSIGMAR1KDM4EMEN1 | |
| SCHEMBL14525251 | 0.88 | MC4R (0.65) | CCR3MC4RSIGMAR1KDM4EMEN1 | |
| SCHEMBL6657455 | 0.86 | CCR3 (0.85) | CCR3MC4RSIGMAR1LMNAPOLB | |
| SCHEMBL22802250 | 0.84 | ALDH1A1 (0.54) | CCR3MEN1KMT2ALMNAPOLB | |
| SCHEMBL22802253 | 0.84 | ALDH1A1 (0.54) | CCR3MEN1KMT2ALMNAPOLB | |
| SCHEMBL25108460 | 0.84 | ALDH1A1 (0.52) | CCR3MEN1KMT2ALMNA | |
| SCHEMBL22802899 | 0.84 | ALDH1A1 (0.54) | CCR3MEN1KMT2ALMNAPOLB | |
| SCHEMBL22802249 | 0.84 | ALDH1A1 (0.54) | CCR3MEN1KMT2ALMNAPOLB | |
| SCHEMBL6657649 | 0.84 | CCR3 (0.82) | CCR3MC4RSIGMAR1LMNAPOLB | |
| SCHEMBL22802902 | 0.83 | LMNA (0.59) | CCR3SIGMAR1LMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9616099-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-04-11 | — | — | US | disclosed |
| US-9603895-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2017-03-28 | — | — | US | disclosed |
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARM INC (US) | 2016-05-19 | — | — | US | disclosed |
| US-9221878-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2015-02-26 | — | — | US | disclosed |
| US-8367618-B2 | Cyclosporin analogues for preventing or treating hepatitis C infection | ENANTA PHARMACEUTICALS, INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20100196316-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | ENANTA PHARMACEUTICALS, INC. | 2010-08-05 | — | — | US | disclosed |
| EP-0632031-B1 | CONDENSED BENZOXA RING COMPOUND, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LTD (JP) | 2000-05-03 | — | — | EP | disclosed |
| EP-0546177-B1 | BENZOPYRAN DERIVATIVE, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LTD (JP) | 1998-01-07 | — | — | EP | disclosed |
| US-5574061-A | ANTILIPEMIC AGENT, ANTIATHEROSCLEROSIS, ACAT INHIBITOR | TEIJIN LIMITED (JP) | 1996-11-12 | — | — | US | disclosed |
| US-5496853-A | FOR TREATING HYPERCHOLESTEROLEMIA | TEIJIN LIMITED (JP) | 1996-03-05 | — | — | US | disclosed |
| EP-0632031-A1 | CONDENSED BENZOXA RING COMPOUND, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1995-01-04 | — | — | EP | disclosed |
| EP-0546177-A1 | BENZOPYRAN DERIVATIVE, PRODUCTION THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING THE SAME | TEIJIN LIMITED (JP) | 1993-06-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160136233-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | CCR3 50/4885MC4R 4323/4885SIGMAR1 2750/4885 |
| US-20100196316-A1 | CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, PTPRC | CCR3 73/4885MC4R 4535/4885SIGMAR1 3317/4885 |
| US-20150056165-A1 | NOVEL CYCLOSPORIN ANALOGUES FOR PREVENTING OR TREATING HEPATITIS C INFECTION | HAVCR2, CHP1, MAVS | CCR3 50/4885MC4R 4323/4885SIGMAR1 2750/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.